Antithrombin Market - RegionalAnalysis
On the basis of region, theglobal AntithrombinMarket is segmented into North America, Latin America, Europe, AsiaPacific, Middle East, and Africa. North America is expected to gain significanttraction in the global antithrombin market, followed by Europe, owing toadoption of robust developed technologies and antithrombin therapies, and highawareness and increasing regulatory approval of drugs in these regions.
Antithrombin is a protein presentin blood that inhibits blood clotting by inactivating thrombin. Antithrombin isproduced by liver and consists of 432 amino acids. There are two major reasonsof antithrombin deficiency, which include acquired antithrombin deficiencycaused due to other diseases such as nephrotic syndrome, liver failure, severetrauma, and metastatic tumors and inherited antithrombin deficiency caused dueto a genetic mutation or abnormality. According to the NCBI (National Centerfor Biotechnology Information), inherited antithrombin deficiency is a rarelyoccurring deficiency and only a maximum of 0.2% of the global population hasthis deficiency. One of the most popular drugs for the treatment ofantithrombin deficiency available in the market is ATryn, which was developedby rEVO Biologics and received the U.S. Food and Drug Administration (FDA)approval in 2009. Antithrombin shows synergistic activity with heparin thatenhances the antithrombin binding with Thrombin (factor II a) and Factor Xa.Antithrombin III blood test is required to measure the amount of deficiency ofantithrombin that is causing the blood to clot more easily than normal.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2018
Antithrombin Market – MarketDynamics
Increasing incidence ofcoagulation disorders, open heart surgeries, and extracorporeal circulationduring hemodialysis is augmenting growth of antithrombin market. According tothe Centers for Disease Control and Prevention (CDC), 2015, around 900,000 peopleis affected from venous thromboembolism every year in the U.S. Furthermore, 5to 8% of the U.S. population has increased risk of suffering from thrombosisdue to one of the several genetic risk factors known as inheritedthrombophilia.
Therapeutic drug pipeline oradvancements in drug administering technology is also expected to fuel growthof antithrombin market. For instance, Fitusiran (ALN-AT3), developed by AlnylamPharmaceuticals, Inc., is a subcutaneously administered, investigational RNAitherapeutic targeting antithrombin (AT). This therapeutic that can be used forthe treatment of hemophilia and rare bleeding disorders (RBDs) is in late stage(Phase 2-phase 3) clinical trial. Moreover, GTC Biotherapeutics, Inc.’s productcalled as ATryn Antithrombin (Recombinant), derived from human blood donors, isused for hereditary antithrombin deficiency and it recently got market approvalin the U.S., thereby significantly contributing to the growth of antithrombinmarket. Therefore, introduction of new types of antithrombin products withdifferent indication over the forecast period is expected to fuel growth of theglobal antithrombin market. Furthermore, increasing use of antithrombin incombination with heparin is likely to support the growth of antithrombinmarket. For instance, heparin resistance in cardiac surgery is likely to createopportunities for use of antithrombin products in anticoagulation therapy.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/antithrombin-market-2018
However, increasing regulationson animal testing have impeded a number of healthcare companies frommanufacturing new drugs, thereby restraining the market growth.
Moreover, improving healthcareinfrastructure in emerging economies such as China and India, and increasingresearch and development activities are contributing towards the growth ofantithrombin market in Asia Pacific region. For instance, in 2016, ChinaBiologic Products, Inc.’s subsidiary, Shandong Taibang Biological Products Co.Ltd., recently obtained approval from the China Food and Drug Administration(CFDA) to begin human clinical trials using its Human Antithrombin III (ATIII)product for the treatment of hereditary and acquired ATIII deficiency which aremore prone during surgical or obstetrical procedures, and treatment ofthromboembolism.
Antithrombin Market – CompetitiveLandscape
The antithrombin market ischaracterized by the presence of few established players. There is stiffcompetition in the market, as these few players occupy major market share. Keyplayers operating in the global antithrombin market include Grifols, ShirePlc., rEVO Biologics Inc., CSL Limited, Kedrion S.p.A, Lee Bisolutions, ScrippsLaboratories Inc., GTC Biotherapeutics, Inc.’s, Green Cross Corp., and BDIPharma.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2018
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
